Comienzos
keyboard_arrow_right
keyboard_arrow_right
Aeterna Zentaris first one fourth revenues increase to $7.
Nutrition

Aeterna Zentaris first one fourth revenues increase to $7.

First Quarter 2011 Highlights Agreement signed with Yakult Honsha Co. Ltd. for the development, manufacture and commercialization of perifosine, in Japan.5 million) upon achieving certain pre-founded milestones, including regulatory and scientific events in Japan, along with double-digit royalties on future net sales of perifosine in Japan. THE BUSINESS has also decided to supply perifosine, on a cost-plus-basis, to Yakult.Receipt of net sales royalty milestone payment of $2.5 million from Cowen Healthcare Royalty Partners, L.P.$1.5 million grant, payable over a three-year period as partial reimbursement of qualifying expenditures, awarded to the ongoing company by the German Ministry of Education and Research to build up, up to the scientific stage, cytotoxic conjugates of the proprietary cytotoxic compound disorazol Z and peptides targeting G-protein coupled receptors, including the luteinizing hormone-releasing hormone receptors.At-the-Market sales contract signed to sell common shares through ATM issuances on the NASDAQ for aggregate gross proceeds not to exceed $19.When among the cancerous cells gains a fresh driver mutation, that cell and its own progeny consider over the entire human population, bringing along all of the original cell's baggage of passenger mutations. ‘Those mutations otherwise would never spread in the population,’ Mirny says. ‘They essentially hitchhike on the driver.’ Related StoriesDiscovery may lead to brand-new anti-metastasis therapies for advanced-stage brain cancers patientsCWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatmentDiscovery might open new doorways to focusing on how melanoma grows and spreads This process repeats five to 10 times during cancer advancement; each time, a fresh wave of damaging travellers is accumulated.